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A B S T R A C T
Objective: To investigate the relationship between intracranial lesions and epileptic seizures in
neuroﬁbromatosis type 1 (NF1) patients.
Background: NF1 is one of the most common autosomal dominant neurocutaneous disorders, and
epilepsy is more prevalent in NF1 patients than in the general population. Epileptic seizures were found
to be related to various types of intracranial lesions in NF1 patients.
Methods: The clinical characteristics of NF1 (1986–2006 in Chung-Gung Memorial Hospital), diagnosed
on the basis of the criteria of the National Institutes of Health Consensus Conference (1988), were
reviewed by 2 neurologists. We diagnosed epileptic seizures of NF1 patients on the basis of clinical
appearances and a history of antiepileptic drugs. Magnetic resonance images were also evaluated by 2
neuroradiologists to conﬁrm the locations of brain tumors or neuroﬁbromatosis bright objects (NBOs).
The locations of NBOs were classiﬁed into 4 categories: cortex and hippocampus, subcortical white
matter, basal ganglia, and infratentorial area. The association between the location of the lesions and the
occurrence of seizure in NF1 patients was analyzed statistically.
Results: The medical records of 630 NF1 patients were reviewed. In this cohort, 37 (5.87%) NF1 patients
had epileptic seizures. The patients include 22 males (59.5%) and 15 females (40.5%). The mean seizure
onset age was 14.8 years (2 months to 72 years). The most common seizure pattern was partial onset
seizures, 3 simple partial seizures, and 14 complex partial seizures. Other seizure types found include 15
primary generalized seizures (2 absence seizures and 13 generalized tonic–clonic seizures), 2 infantile
spasms, and 3 unclassiﬁed.
A total of 172 (23 with epilepsy and 149 without epilepsy) NF1 patients underwent MRI
examinations. NBOs were identiﬁed in 16 (69.6%) epilepsy patients and in 108 (72.5%) patients without
epilepsy. The location or the number of these intracranial lesions does not show signiﬁcant correlation
with the occurrence of epilepsy in our cohort. Among 11 NF1 patients with intracranial tumors, 4
patients had seizures (36.36%), vs. 19 out of 161 NF1 patients (11.80%) without tumors.
Conclusion: The occurrence of epileptic seizures in NF1 patients is related to intracranial tumors but not
to NBOs.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Two distinct types of neuroﬁbromatosis exist: neuroﬁbroma-
tosis type 1 (NF1) and neuroﬁbromatosis type 2 (NF2). NF1 is a
common autosomal dominant disorder in human with an
incidence of 1 in 2500–3300 and high rate of new mutations.1–5
The NF1 gene is located in chromosome 17q11.2 and codes for a* Corresponding author at: Section of Epilepsy, Department of Neurology, Chang-
Gung Memorial Hospital, Chang-Gung University College of Medicine, 199 Tung-
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.04.016large tumor suppressor protein called neuroﬁbromin. In addition
to the major presentation of subcutaneous neuroﬁbromas, cafe´-au-
lait spots, Lisch nodules, axillary freckling, and skeletal dysplasia,
NF1 may be complicated with epilepsy, various types of
intracranial lesions, headache, hydrocephalus, lacunar infarction,
mental retardation, intraspinal neuroﬁbroma, peripheral nerve
sheath tumors, and polyneuropathy.5
Neuroﬁbromatosis bright objects (NBOs), also known as
unidentiﬁed bright objects (UBOs), are focal hyperintensity lesions
in T2-weighted magnetic resonance imaging (MRI) of NF1
patients.6–11 The overall frequency of NBOs is 43–77% with high
frequency (93%) in patient <15 years old.12 The common locations
of NBOs are the globus pallidus, thalamus, hippocampus, and
brainstem.9–12,14,30 Although most of these lesions remain stablevier Ltd. All rights reserved.
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transformation into brain gliomas.9–17 The mechanism of NBOs
development is still unclear.
Epilepsy is one of the most common complications of NF1, with
the prevalence approximately from 4.2% to 6% in NF1
patients.3,18,19 The much higher incidence of epilepsy in NF1
patients may be related to the coexistence of intracranial tumors or
NBOs.18–20 This retrospective study analyzed the clinical features
and MRI characteristics of 630 NF1 patients to clarify the
relationship of epilepsy and intracranial lesions.
2. Subjects and methods
We performed a retrospective analysis on clinical data of 630
patients who were diagnosed as having NF1 in our hospital from
January 1986 to December 2006. The diagnosis of NF1 was
conﬁrmed by 2 neurologists (Drs. Hsieh and Wu) according to the
National Institutes of Health Consensus Conference criteria.1 The
inclusion criteria included 2 or more of the following:Table 1
Total 37 neuroﬁbromatosis 1 patients with epilepsy (patient 1 to patient 23 had MRIs
No. Sex/age (y/o) Onset age Pattern MRI ﬁnding 
Tumor 
1 M/48 40 y/o SPS R’t falx meningioma
2 F/14 8 y/o CPS with G (–) 
3 M/13 6 y/o CPS (–) 
4 F/33 32 y/o GTCS L’t thalamus astrocy
5 F/38 32 y/o CPS bil optic glioma; Lt 
callusum and P–O a
6 M/23 14 y/o GTCS (–) 
7 M/10 5 y/o GTCS (–) 
8 M/14 4 y/o CPS with G (–) 
9 M/25 6 y/o GTCS (–) 
10 F/8 1 y/o Infantile spasm (–) 
11 F/10 4 y/o GTCS (–) 
12 M/5 1 y7 m GTCS (–) 
13 M/8 3 y/o CPS (–) 
14 F/13 5 y/o CPS (–) 
15 M/12 4 y/o CPS with G (–) 
16 F/14 9 y/o Absence (CAE) (–) 
17 M/6 2 month Infantile spasm;
myoclonic seizure
(–) 
18 F/25 6 y/o CPS with G 
19 M/14 8 y/o un (–) 
20 M/54 52 y/o GTCS (–) 
21 F/11 10 y/o Absence (CAE) (–) 
22 M/15 6 y/o CPS with G Brain stem glioma 
23 F/28 28 y/o CPS (–) 
24 F/81 72 y/o CPS (EPC) 
25 F/48 31 y/o SPS, CPS 
26 M/8 2 y 7 month GTCS 
27 M/40 32 y/o CPS with G 
28 M/14 6 y/o GTCS 
29 M/48 un GTCS 
30 F/51 46 y/o CPS 
31 M/18 15 y/o un 
32 M/11 4 y/o GTCS 
33 M/15 7 y/o GTCS 
34 F/17 9 y/o un 
35 F/8 2 y/o CPS 
36 M/23 17 y/o GTCS 
37 M/12 4 y/o SPS, CPS 
NBOs: neuroﬁbromatosis bright objects; M: male; F: female; Rt: right; Lt: left; bil: bilatera
P: parietal; C: central; T: temporal; O: occipital; SWC: spike-waves complex.
GTCS: generalized tonic–clonic seizure; SPS: simple partial seizure; CPS: complex partial
secondary generalization; EPC: epilepsia partialis continuca.
Localization of NBOs: 1, cortex; 2, HA – hippocampus and amygdala; 3, subcortical w
cerebellum; 9, midbrain; 10, pons; 11, medulla.
Frequency of seizure: A, seizure-free for more than 1 year; B, less than 5 seizures per ye
(unknown).
a Advised to stop taking anti-epileptic drugs by doctor’s suggestion. Six or more cafe´-au-lait spots.
 Two or more neuroﬁbromas.
 Skin-fold freckling in the axilla or groin.
 Optic glioma.
 Two or more Lisch nodules.
 A distinctive bony lesion such as dysplasia of the sphenoid bone
or thinning of a long-bone cortex.
 A ﬁrst-degree relative (parent, sibling, or offspring) with NF1
diagnosed using the above criteria.
Patients with NF2 or other neurocutaneous diseases that were
misdiagnosed as NF1 were excluded.
Patients with epileptic seizure were deﬁned as ‘‘having 1 or
more unprovoked clinically deﬁned seizures and consuming
antiepileptic drugs.’’ This stringent deﬁnition was employed for
the usage of antiepileptic therapy should be recorded in one’s
medical history in order to ensure high reliability of the diagnosis
of epilepsy. With this deﬁnition, 37 NF1 patients were found to
have epileptic seizures. Additionally, encephaloelectrography
(EEG) was used to conﬁrm the diagnosis of seizure in 35 out of).
EEG Frequency
Location of NBOs Epileptiform discharges
 (–) (–) A
4, 5, 11 bil F, T A
1, 4, 5, 8, 9, 10 Lt F, Rt T A
toma 3, 5, 10 ND C (dead)
corpus
strocytoma
2, 8, 9 (–) A
3, 8, 11 Rt C, P; Lt C, T, F A
4, 5, 9, 10 R’t F Aa
5, 8, 9, 10 Rt P Aa
5 (–) A
(–) bil F, T (R > L) C
4, 5 Rt C, P A
(–) (–) Aa
2, 4, 5, 6, 8, 9, 10, 11 Rt F, T Aa
(–) Bil F (L > R) C
(–) Bil C, T (L > R) B
3, 4 Generalized SWC 3 Hz Aa
6 Rt P T O A
2, 3, 4, 5, 6 F7, T3 C
2, 5, 8 ND Ba
5 (–) A
(–) Generalized SWC 3 Hz B
2, 4, 5, 8 bil hemi X (dead)
(–) (–) B
Lt F C B (dead)
(–) Aa








Rt F; Lt T X
Lt P C T Xa
Rt P, T X
bil T, Lt F Aa
l; hemi: hemisphere; (–): nil; un: unknown or not deﬁned; ND: not done; F: frontal;
 seizure; CAE: childhood absence epilepsy; CPS with G: complex partial seizure with
hite matter; 4, globus pallidus; 5, thalamus; 6, putamen; 7, internal capsule; 8,
ar; C, >5 seizure attacks per year, or even >1 per month; and X, loss to follow-up
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ﬁrst seizure, EEG ﬁnding, and antiepileptic drug use of each
participant were recorded. The frequency of seizures after
treatment was deﬁned according to the chart records as follows:
A, seizure-free for more than 1 year; B, less than 5 seizures per
year; C, >5 seizure attacks per year, or even >1 per month; and X,
loss to follow-up >2 years or unknown.
MRI of brain, head, and neck was performed to delineate the
intracranial lesions. The indications for these MRI studies were not
conﬁned to the neuroimaging investigation of NF1, but include
stroke, seizure, mental retardation, or other symptoms such as
blurred vision, headache, and focal weakness. The MRIs were
evaluated by 2 neuroradiologists (CJ Wang and SC Chin) and 2
neurologists. The number and distribution of intracranial tumors
and any focal hyperintensities of T2-weighted signals, and the
hypo- or iso-intensities of T1-weighted signals on MRI, were
reviewed. Patients were assigned into 2 groups (with epilepsy and
without epilepsy) for analysis. The locations of NBOs were
classiﬁed into 4 major areas: cortical area (including hippocampus
and amygdala), subcortical white matter, basal ganglia, and
infratentorial area (including cerebellum and brain stem). x2 tests
were used to determine the correlation of various locations of
NBOs and the prevalence of epileptic seizure in NF1 patients.
Statistical analysis was performed with SPSS ver. 15. The
signiﬁcance level was deﬁned as p < 0.05.
3. Results
Six hundred and thirty patients (332 males and 298 females)
were conﬁrmed as having NF1 in CGMH. Their mean age was
29.5  19.0 years. This series comprised a total of 172 patients (75
females [43.6%] and 97 males [56.4%]) who had MRI studies of the
brain, or head and neck. We calculated intracranial lesions based on
those who underwent MRI studies.
In 630 patients diagnosed as having NF1, 37 (5.9%) were
ascertained to have had 1 or more unprovoked seizures and have
taken antiepileptic drugs. The clinical manifestations of these NF1
patients with epileptic seizures are depicted in Table 1. No familial
history of epilepsy was reported in this group of patients (22 males
[59.5%] and 15 females [40.5%]). The mean age at onset of seizures
was 14.8 years (2 months to 72 years). The periods of 37 followed
patients was 68.4  46.5 months (1–228 months), and mean
duration of using antiepileptic drugs was 54.8  50.1 months (1–
228 months). There were 21 (56.8%) patients received antiepileptic
monotherapy and 16 (43.2%) patients with polytherapy. Seventeen of
the 30 were seizure free (7 patients off and 10 patients on
antiepileptic medication), 7 had 5 seizures per year, and 6 patients
had >5 seizures per year.
The most common seizure pattern was primary partial onset
seizure (PS) (n = 17). Among this partial-onset seizure group, the
seizure pattern of 14 patients was classiﬁed as complex partial
seizures (CPS) and 6 had secondary generalization. Other patterns
found included 2 absence seizures (AS) and 2 infantile spasms. In
35 patients who had 1 or more EEG recording, 24 (68.6%) had
recorded epileptiform discharges: 12 had discharges localized in
the unilateral hemisphere and the other 12 had multifocal
discharges (involved bilateral hemispheres), including 3 Hz
generalized spike-and-wave complexes in 2 patients. Two patients
had no EEG data but were diagnosed as having epilepsy from
clinical history or presentations.
Twenty-three (62.2%) of the 37 NF1 patients with epilepsy had
MRI of the brain or head and neck. Four patients were found to
have brain tumors, including 1 meningioma and 3 supratentorial
gliomas. Other tumors such as optic pathway glioma and pituitary
adenoma were also noted. Sixteen (69.6%) patients had focal areas
of prolonged T2-weighted signals on MRI, which we called NBOs.The common locations of NBOs were the basal ganglia, cerebellum,
brain stem, and subcortical white matter (Tables 1 and 2).
Of the 593 NF1 patients without epilepsy, 149 (25.1%) received
MRIs. The neuroimaging ﬁndings include 108 (71.8%) NBOs and 7
(5.4%) intracranial tumors (3 meningiomas and 4 gliomas) that
may be related to seizure (Table 2).
4. Discussion
NF1 was previously considered a disease with peripheral
manifestations, such as cafe´-au-lait spots, peripheral neuroﬁbro-
mas, Lisch nodules, and axillary freckling.1–3 Diagnosis of NF1 is
typically made during childhood, based on clinical ﬁndings. A
positive family history is noted in about 50% of cases. The
consensus among the experts indicates that patients with NF1
have not only peripheral lesions such as a subcutaneous mass or
neuroﬁbroma but also some CNS lesions5 such as optic pathway
glioma. Moreover, NF1 patients have a higher incidence of tumors
than the general population.2,3 The incidence of abnormalities
(tumor, NBOs, or both) in brain MRIs was as high as 80.1% in our
series, which suggests that the brain imaging study is essential in
investigating the presence of any intracranial lesion in each NF1
patient, whether or not he or she had neurological deﬁcits of CNS.
One of the most common complications of NF1 is seizure.
Roughly 4.2–6% of NF1 patients have epileptic seizures, with the
prevalence approximately twice of that in the general popula-
tion.18,19 In fact, seizure could be the ﬁrst presentation in NF1
patients. Riccardi, Friedman, and Birch reported epileptic seizure
prevalence of 5% and 6.4%3,18,19 in the NF1 population. Previous
reports showed that the lifetime prevalence of epilepsy is higher in
patients with NF1 compared with the general population.19 The
exact prevalence of epilepsy in the NF1 population is difﬁcult to
determine because of the following reasons: ﬁrst, the subtlety of
partial onset seizure might be ignored during the devastating
course of the illness. Second, there are different criteria for deﬁning
seizures, as have been used in previous studies. Some authors only
took account of unprovoked seizures19 in computing the preva-
lence, whereas other authors included NF1 patients with only
febrile convulsion.18 By contrast, Riccardi excluded from those NF1
patients in whom epilepsy was related to intracranial tumors.3 We
deﬁned ‘‘NF1 patients with epilepsy’’ as those having 1 or more
seizures and were taking antiepileptic drugs regardless of the
aetiology of seizures. Therefore, the prevalence of unprovoked
seizure in our series will probably be higher than in other studies.
Thirty-seven (5.9%) patients were diagnosed as having epilepsy
and were taking antiepileptic drugs in our series. The prevalence of
epileptic seizures in our study is higher than that in the previous
data reported by Riccardi3 (5%) and Korf et al.18 (4%). It is
noteworthy that since antiepileptic medication use is one of the
criteria for deﬁning epileptic seizure in the present study, it may
lead to the underestimation of the prevalence in our cohort. This
may be explained by the bias related to the speciﬁc interest of our
institute in studying plastic and orthopedic diseases in Taiwan.
Riccardi brieﬂy reported both major and minor motor seizures
in NF1 patients occurring at a frequency of about 5%; the seizure
type was usually primary generalization rather than being focal in
nature.3 However, Korf18 and Kulkantrakorn19 both reported that
partial onset seizure, especially CPS with or without secondary
generalization, were slightly more common than primary gener-
alized seizures in NF1. In our series, the most common seizure was
also partial onset seizure (n = 17, 46%), especially CPS (n = 14,
37.8%), followed by primary generalized seizures (n = 15, 40.5%),
among which GTCS is the most common (n = 13, 35%). In addition,
Kulkantrakorn19 and Vivarelli20 had reported 2 cases of AS, each of
which had NBOs in the basal ganglia; Korf18 also reported 1 case of
AS but no NBOs. We also had 2 cases of AS (see patients 16 and 21,
Table 2
MRI ﬁndings in NF1 patients with or without epilepsy.
MRI (patient N = 172; M:F = 97:75) NF1 with epilepsy NF1 without epilepsy
23 149
Age (y/o) 22.2  16.3 22.7  16.7
Gender (M:F) 13:10 84:65
Supratentorial tumors 4 (17.4%) 7 (4.7%)
Glioma 3 (13.0%) 4 (2.7%)
Meningioma 1 (4.3%) 3 (2.0%)
Optic pathway glioma (OPG) 2 4
Pituitary adenoma 0 1
Infratentorial tumors (cerebellum tumor, brain stem tumor, cavernoma) 1 6
The presence of NBOsa and their locations 16 (69.6%) 108 (72.5%)
Cortical area and hippocampus, amygdala (Cx, HA) 6 (26.1%) 29 (19.5%)
Subcortical white matter (WM) 4 (17.4%) 19 (12.8%)
Basal ganglia (GP, T, P, IC) 15 (65.2%) 86 (57.7%)
Infratentorial (CB, M, Ps, Md) 11 (47.8%) 70 (47.0%)
NBOs: neuroﬁbromatosis bright objects; Cx: cortex; HA: hippocampus and amygdala; WM: subcortical white matter; GP: globus pallidus; T: thalamus; P: putamen; IC:
internal capsule; CB: cerebellum; M: midbrain; Ps: pons; Md: medulla.
a NBOs could be present in more than one location in an individual.
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diagnosis of childhood absence epilepsy (CAE) is conﬁrmed
according to clinical presentations and typical EEG ﬁndings. To
the best of our knowledge, this is the ﬁrst report to dissect the
relationship between the anatomical distribution of intracranial
lesions and the pattern of seizure in an NF1 cohort. We conclude
that no signiﬁcant correlations were found among intracranial
lesions, EEG, and seizure patterns.
For epileptiform discharges in EEG analysis, 5 of our patients
who presented with general onset seizures (33%) had focal
discharges. It is hypothesized that seizures in NF1 may progress
rapidly, which may cause the witness of the events to neglect the
initial symptoms or signs of partial onset seizures. Therefore, the
prevalence of partial onset seizure in NF1 may have been
underestimated in our series. The other explanation for the higher
rate of seizures in NF1 patients is that they may have a lower
threshold for the abnormal epileptiform discharges; that is, the
subclinical focal discharges could evolve into clinical generalized
seizure. This hypothesis is supported by the ﬁnding that
neuroﬁbromin, the protein product of the NF1 gene, is abundantly
expressed in the cerebral cortex during embryonic development. In
particular, neuroﬁbromin appears to be involved both in the
differentiation of the neuronal neurotransmitter phenotype and in
the formation of synapses.22 The expression of neuroﬁbromin may
result in an aberrant neural network that lowers the threshold for
abnormal epileptic activity. This correlation between the particu-
lar seizure pattern and the location of discharges needs further
investigation.21,22
Neuronal heterotopia was reported to be the cause of seizures
in some NF1 patients; however, this was not found in our series.
The relationship between epilepsy and brain malformation and/or
neuronal migrational disorders in NF1 is not well established,
compared with other neurocutaneous disorders such as tuberous
sclerosis23 or the Sturge–Weber syndrome.25
Brain tumors in NF1 are not uncommon, but the association
between intracranial tumors and epilepsy in NF1 was rarely
discussed before. Vivarelli20 reported a relatively high incidence of
epileptic patients with NF1 and cerebral tumors (ﬁve of 14
patients, 35.7%). In three of these, seizures were the ﬁrst clinical
manifestation. But in other studies, the incidence of intracranial
tumor was only 9.52% in 2119 or 0% in 22 NF1 patients with
epilepsy.18 In this study, the overall the incidence of intracranial
tumors was higher in NF1 patients with epilepsy than in those
without epilepsy (see Table 2). Among 11 NF1 patients with
intracranial tumors, 4 patients (36.36%) had epilepsy. On the otherhand, there are only 19 patients (11.80%) had epilepsy in 161 NF1
patients without tumors. Lesions of optic pathway glioma,
pituitary adenoma, and cerebellar tumor were not included in
this analysis because special disease entity with seizure (hemi-
facial spasm in childhood cerebellar tumor27,28 and seizure in
complicated pituitary adenoma29) and no case description of OPG
and related seizure.
In previous reports, the overall frequency of NBOs in NF1
patients is 43–77%.9,14 In children with NF1, 93% have NBOs, which
are common in ages 4–10 years.12 The most common anatomical
site is the globus pallidus (GP, 30.4%), followed by the cerebellum
(23.5%) and midbrain (16.2%).9,14 In our previous study, NBOs were
most commonly found in the GP and thalamus (15.4%), and then in
the cerebellum and subcortical white matter (11.54%).30 Notably,
only few NBOs had been reported to be found in the subcortical
white matter and cortex. Analyzing the locations of the NBOs in our
172 patients using MRI studies, we found that the most common
location is the globus pallidus (GP), 81 (47.09%), followed by 68 in
the thalamus (39.53%) and 56 in the cerebellum (32.56%). Twenty-
three NBOs were observed in the subcortical white matter
(13.37%), 7 in the cortex (4.07%), and 32 in the hippocampus
and amygdala (18.60%).
The above locations of NBOs were classiﬁed into 4 major areas.
The most common location is the basal ganglia (65.2% in the
epileptic group and 57.7% in the nonepileptic group), and then the
infratentorial area (47.8% in the epileptic group and 47.0% in the
nonepileptic group) (Table 2). Although it does not reach statistical
signiﬁcance, the number of NBOs located in the basal ganglia,
cortical area, and subcortical white matter was greater in the
epileptic group (65.2%, 26.1%, and 17.4%, respectively) than in the
nonepileptic group (57.7%, 19.5%, and 12.8%, respectively). The
basal ganglia and subcortical white matter may be relative
predisposing locations in the induction of epilepsy in NF1 patients,
just as the cortical area, hippocampus, and amygdala are well
known to be important locations in most symptomatic seizures.
Further investigation is needed to deﬁne the underlying mecha-
nism of this observation.
No signiﬁcant differences were found between the incidence of
NBOs in the epileptic and the nonepileptic groups (69.6% and
72.5%). On the other hand, if we analyzed NBOs in NF1 patients, 16
patients had epilepsy (12.90%), vs. the other 7 out of 48 NF1
patients (14.58%) without NBOs. The MRIs in Fig. 1 demonstrate
the presence of several NBOs in NF1 patients with and without
epilepsy. In conclusion, NBOs is not considered as a contributing
factor of epilepsy in NF1 patients.19,20
Fig. 1. The MRI studies in 2 NF1 patients. Patients could have similar locations of NBOs, but different clinical presentations. Patient 1 (Table 1, patient 13) has epilepsy (1a–c,
thin arrow): NBOs located at cerebellum, medulla, hippocampus, midbrain, and globus pallidus, thalamus. Patient 2 has no epilepsy (2a–c, thick arrow): NBOs located at
cerebellum, hippocampus, midbrain, and globus pallidus, thalamus. *NBOs: neuroﬁbromatosis bright objects.
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patients were well controlled on 1 or more antiepileptic drugs
(groups A and B, see Table 1), and a total of 10 (27.0%) were advised
to stop taking drugs by clinical physicians. Only 6 were poorly
controlled by history, among them 1 patient who had thalamus
tumor (patient 4) and another who had cerebral palsy (CP) with
mental retardation (patient 10). One patient had CP (patient 14)
and 1 had a history of meningitis at the age of 10 months (patient
18). There is no obvious risk factor or organic brain lesion related to
the poor prognosis in the other 2 patients. Seven patients were lost
to follow-up. Status epilepticus was not encountered in any patient
during the follow-up period; only 1 patient had a history of
epileptic partialis continuca (EPC), which was well controlled. In
the analysis of medication use, no speciﬁc antiepileptic drugs were
seen to be particularly effective for NF1 patients with epilepsy. In
our series, 21 patients were able to have good seizure control
response using a single drug therapy, while 16 were on
polytherapy. The prognosis of epilepsy in our NF1 patients is
satisfying that more than half of patients could be controlled by
only 1 antiepileptic drug and majority of the patients will be
seizure free. This ﬁnding is similar to previous studies,19,20 and
better than the prognosis of tuberous sclerosis (20–25% patients
were drug resistant)24 and Sturge–Weber syndrome (50% patients
had status epilepticus).25,26
5. Conclusion
From our study, the occurrence of epileptic seizures in NF1
patients is related to intracranial tumors (supratentorial
meningioma or glioma) but not to NBOs. In this study, most
patients with brain lesions did not present with seizures. Our
ﬁndings suggest that most of the brain lesions, either tumors or
NBOs, in NF1 patients are often silent and asymptomatic. The
positive ﬁnding rate with MRI is 74.4% in this study. Therefore,
neuroimaging study for patients with NF1 is essential todetermine the existence of any intracranial lesion that may
need further medical attention.
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